Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)

Ceiling: $275,000
Applications Due: Closed
Federal
US Department of Health & Human Services (National Institutes of Health)

This funding opportunity supports innovative research into how inflammasome activation affects individuals with HIV and substance use disorders, aiming to uncover mechanisms and potential therapeutic targets to improve health outcomes.

Description

The scientific objective of this Funding Opportunity Announcement is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

Eligibility
States
All
Regions
All
Eligible Entities
State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal organizations, Public housing authorities, Native American tribal organizations, Nonprofits

Funding

Program Funding
Visit Source
Award Ceiling
$275,000
Award Floor
Visit Source
Award Count

Timing

Posted Date
October 17, 2023
App Status
No Longer Accepting Applications
Pre-app Deadline
Visit Source
Application Deadline
October 28, 2024

Funder

Funding Source
Visit Source
Source Type
Federal
Contact Name
Visit Source
Contact Email
Click to email
Contact Phone
--

Why Organizations Trust GrantExec

$78.81B
Available Funding
7,151
Active Grants
224
New Grants Analyzed This Week